Antrag nach EU-Verordnungen 1049/2001 sowie 1367/2006 Sehr Antragsteller/in auf Basis der Verordnungen 1049/2001 sowie 1367/2006 bitte ich Sie um Übersendung von Dokumenten, die folgende Informationen enthalten:

Dear Sir/Madam **ASK-81593 ( https://servicedesk.ema.europa.eu/jira/browse/ASK-81593 ) - Korrespondenz mit deutschen Behörden zum tlw. Impfstopp der AstraZeneca-Impfung am 30.03.2021 [#217097] received on 6/Apr/21** Thank you for submitting your request. This is an automated response to confirm that we have received your request; please do not respond directly to this message as this email address is not monitored. A member of Agency staff will now review your request. We will send an acknowledgement of receipt to the email address you have provided, quoting your unique reference number. We endeavour to review all requests as soon as possible, but no later than within 48 hours of receipt, during our normal business hours (see Business hours and holidays ( https://www.ema.europa.eu/en/about-us/contact/business-hours-holidays )). Should you need to contact us in relation to this request please submit your updated query through the webform ( https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency ), quoting the ASK reference number given above. Kind regards,

Dear Requester, Thank you for contacting us on 6 April 2021. We hereby acknowledge receipt of your application for access to documents, which was registered on the same day under reference number ASK-81593. We will deal with your request as soon as possible and in accordance with the principles and limits established in Regulation (EC) 1049/2001 regarding public access to European Parliament, Council and Commission documents (the Regulation), as applicable to the EMA pursuant to Article 73 of Regulation (EC) 726/2004. In accordance with the Regulation, you will receive a reply via a secure Eudralink within 15 working days. The Agency may extend this period by a further 15 working days in exceptional circumstances in accordance with the Regulation. Please note that the European Medicines Agency is currently operating within a business continuity plan to ensure operational continuity following its relocation to Amsterdam and during the continuing COVID-19 pandemic. Whilst every effort is being made to process your request as soon as possible, you should be aware that due to these exceptional circumstances, we may have to extend the deadline as outlined above. Should such an extension be applied by the Agency, you will be informed at the time. In case this email becomes publicly available, please redact personal data such as the first name and surname of the sender, e-mail address as well as any other personal data, as relevant. The Agency considers this information to be protected personal data in the meaning of Article 3(1) of Regulation (EU) No 2018/1725 and Article 4(1) of the General Data Protection Regulation EU 2016/679. Personal data is information that permits to identify a natural person. Kind regards,

Sehr Antragsteller/in Danke für Ihre E-Mail. Bitte beachten Sie, dass Ihre Anfrage mit der Referenznummer ASK-81593 am 6. April um 21:43 Uhr eingegangen ist. Die Frist von 15 Arbeitstagen läuft daher morgen ab. Sollte diese Frist verlängert werden müssen, werden Sie von uns informiert. Mit freundlichen Grüßen,

Dear Sir/Madam, I write with an update on the above request. Unfortunately, due to the current high volume of requests resulting in an excessive workload, we are not in a position to issue a decision concerning the release of the above request within the initial timeline of 15 working days provided for in Article 7(1) of Regulation (EC) No 1049/2001 ("Regulation"). The Agency is required, in these exceptional circumstances, to extend this deadline by another 15 working days in accordance with Article 7(3) of the Regulation. This decision to extend is in line with the principle set out in our Policy on access to documents (available at https://www.ema.europa.eu/en/documents/other/policy/0043-european-medicines-agency-policy-access-documents_en.pdf ) which states that the Agency will apply the principle of proportionality in order to avoid the core business tasks of the Agency and its performance being jeopardised by the administrative workload related to activities within Regulation 1049/2001. Under the above stated Regulation, you will receive a reply within 30 working days (initial period of 15 working days + 15 working days extension). The deadline has therefore been extended to 25 May 2021 Please accept our apologies for any inconvenience that this may cause. Documents Access and Publication Service Stakeholders and Communication Division European Medicines Agency Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands Telephone +31 (0)88 781 6000 www.ema.europa.eu<https://www.ema.europa.eu/en> | For directions, see How to find us<https://www.ema.europa.eu/en/about-us/contact/how-find-us> Follow us: [Twitter-icon] <https://twitter.com/EMA_News> [RSS-icon] <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/rss_feed.jsp&mid=WC0b01ac058007c0e8> [Youtube-icon] <https://www.youtube.com/user/emainfo> [EMA_logo]<http://www.ema.europa.eu/ema/> This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately. Classified as confidential by the European Medicines Agency ________________________________________________________________________ This e-mail has been scanned for all known viruses by European Medicines Agency. ________________________________________________________________________

+++++++++++++++++++++++++++++++++++++++++++++ You have been sent a package by "European Medicines Agency" <<Name und E-Mail-Adresse>> To retrieve your package use the hyperlink below https://eudralink.ema.europa.eu/dl.php?d=28785ca571a851a09dc1872eeeb21487 The package will expire on Tue, 17 Aug 2021 16:12:30 +0200 HOW TO PICK UP YOUR PACKAGE: If the Web address above is highlighted, click on it to open a browser window. You will automatically be taken to the package. If the Web address above is not highlighted, follow these steps: - Open a Web browser window. - Copy and paste the entire Web address into the "location" or "address" bar of the browser. - Press enter. Once you arrive at the Web page, you can access the package. +++++++++++++++++++++++++++++++++++++++++++++

Dear Requester, The decision letter regarding the above request has just been released to you via a secure Eudralink. Please ensure that you download and save the document before the package expires. Please note that you will need to enter a password to access this Eudralink package. Your unique password takes the following format: ask-XXXX-YYYY It is the ASK reference number for this request (ask-XXXX, written exactly as it appears in the subject line ) + the year (-YYYY) in which you submitted your request to the Agency In case this email becomes publicly available, please redact personal data such as the first name and surname of the sender, e-mail address as well as any other personal data, as relevant. The Agency considers this information to be protected personal data in the meaning of Article 3(1) of Regulation (EU) No 2018/1725 and Article 4(1) of the General Data Protection Regulation EU 2016/679. Personal data is information that permits to identify a natural person. Kind regards,